• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Products & Possibilities

Our co-lead clinical development candidates are KP415 – a prodrug product of dexmethylphenidate (d-MPH) with potential improvements over existing extended-release ADHD treatments, and KP484 – a “super-extended release” d-MPH prodrug product for the treatment of ADHD in patients that require a very long duration of therapy.

In addition, we have gained approval of Apadaz®, an immediate-release, benzhydrocodone/acetaminophen combination product for the treatment of acute pain. 

Our Value Proposition

KemPharm® believes that its LAT™ technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

Learn more about LAT™

October 30, 2018

Featured Publication

KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ® 

Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call Today, Tuesday, October 30, 2018 at 4:30 p.m. ET to Discuss the Collaboration Highlights: KemPharm to receive up […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture

  • 11

    Apr

    19

  • KemPharm Completes KP415 Pre-NDA Meeting with...

  • 13

    Mar

    19

  • KemPharm Provides Update on APADAZ®

  • 05

    Mar

    19

  • KemPharm to Present at Upcoming Investor Conf...